Abstract
The mucosal immune response to HIV weighs in heavily on the battle against it, as the majority of infections occur via the mucosal route. The antibody response in the mucosae, specifically the genital tract, is characterized by binding and, in some studies, neutralizing HIV-specific IgG and IgA antibodies. Ample evidence, however, points to discrepancies and difficulties in the detection of HIV-specific IgA in HIV-positive subjects, and an even more pronounced divide surfaces in studies done with individuals exposed to HIV, but uninfected. Reports in the literature detail HIV-specific (in some cases, neutralizing) IgA antibodies, in the absence of specific IgG, in the serum and mucosal secretions of virusexposed, seronegative subjects; this has given rise to speculation that HIV-specific IgA provides a protective immune response to the virus in high-risk individuals who remain seronegative. Contradictory results, however, describe the absence of both IgA and IgG HIV antibodies in the mucosal secretions of similar cohorts. Considering the importance of the antibody response to ascertaining the correlates of HIV immunity, as well as on vaccine research and development, this review addresses the relevant studies and their implications.
Keywords: HIV, antibody response, immunoglobulin
Current HIV Research
Title: Neutralizing Antibodies in Mucosal Secretions: IgG or IgA?
Volume: 5 Issue: 6
Author(s): Rashada Alexander and Jiri Mestecky
Affiliation:
Keywords: HIV, antibody response, immunoglobulin
Abstract: The mucosal immune response to HIV weighs in heavily on the battle against it, as the majority of infections occur via the mucosal route. The antibody response in the mucosae, specifically the genital tract, is characterized by binding and, in some studies, neutralizing HIV-specific IgG and IgA antibodies. Ample evidence, however, points to discrepancies and difficulties in the detection of HIV-specific IgA in HIV-positive subjects, and an even more pronounced divide surfaces in studies done with individuals exposed to HIV, but uninfected. Reports in the literature detail HIV-specific (in some cases, neutralizing) IgA antibodies, in the absence of specific IgG, in the serum and mucosal secretions of virusexposed, seronegative subjects; this has given rise to speculation that HIV-specific IgA provides a protective immune response to the virus in high-risk individuals who remain seronegative. Contradictory results, however, describe the absence of both IgA and IgG HIV antibodies in the mucosal secretions of similar cohorts. Considering the importance of the antibody response to ascertaining the correlates of HIV immunity, as well as on vaccine research and development, this review addresses the relevant studies and their implications.
Export Options
About this article
Cite this article as:
Alexander Rashada and Mestecky Jiri, Neutralizing Antibodies in Mucosal Secretions: IgG or IgA?, Current HIV Research 2007; 5 (6) . https://dx.doi.org/10.2174/157016207782418452
DOI https://dx.doi.org/10.2174/157016207782418452 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Norlichexanthone Isolated from Fungus P16 Promotes the Secretion and Expression of Adiponectin in Cultured ST-13 Adipocytes
Medicinal Chemistry Postoperative Complications in Hemorrhoidal Disease and Special Conditions
Reviews on Recent Clinical Trials Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents Antioxidant Therapy in Alzheimers Disease: Theory and Practice
Mini-Reviews in Medicinal Chemistry Cytokines in HIV-Infection - Inflammatory Damage or Therapeutic Potential?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Sex Steroid Hormones, Cardiovascular Diseases and The Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Kinases as Targets for ENaC Regulation
Current Molecular Pharmacology TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology The Two Faces of Protein Palmitoylation in Islet β-Cell Function: Potential Implications in the Pathophysiology of Islet Metabolic Dysregulation and Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Transcriptional Regulation in Mammalian Pituitary Development and Disease
Current Genomics Recent Developments in Delivery of Nucleic Acid-Based Antiviral Agents
Current Pharmaceutical Design An Alternative “Trojan Horse” Hypothesis for COVID-19: Immune Deficiency of IL-10 and SARS-CoV-2 Biology
Endocrine, Metabolic & Immune Disorders - Drug Targets HMG-CoA Reductase Inhibitors: Effects on Chronic Subacute Inflammation and Onset of Atherosclerosis Induced by Dietary Cholesterol
Current Drug Targets - Cardiovascular & Hematological Disorders Therapeutic Potentials of Recently Identified PLD Inhibitors
Current Chemical Biology Pharmacokinetic-Pharmacodynamic Modeling of Antihypertensive Drugs: From Basic Research to Clinical Practice
Current Hypertension Reviews The use of Immunoglobulin Therapy in Primary Immunodeficiency Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Aquaporins as Targets for Drug Discovery
Current Pharmaceutical Design Trends in Mitochondrial Therapeutics for Neurological Disease
Current Medicinal Chemistry Extracellular Matrix in Atherosclerosis: Hyaluronan and Proteoglycans Insights
Current Medicinal Chemistry Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas
Current Drug Discovery Technologies